The Effects of Denosumab on the Pharmacokinetics (PK) of Midazolam

NCT01221727 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Postmenopausal Osteoporosis

Interventions

DRUG: Denosumab
DRUG: Midazolam

Sponsor

Amgen